{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T14:14:05Z","timestamp":1770473645746,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[1997,6,1]],"date-time":"1997-06-01T00:00:00Z","timestamp":865123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[1997,6]]},"DOI":"10.1006\/exer.1997.0292","type":"journal-article","created":{"date-parts":[[2002,10,7]],"date-time":"2002-10-07T14:19:19Z","timestamp":1034000359000},"page":"971-978","source":"Crossref","is-referenced-by-count":340,"title":["Effects of Thalidomide and Related Metabolites in a Mouse Corneal Model of Neovascularization"],"prefix":"10.1006","volume":"64","author":[{"given":"B\u00c4RBEL M.","family":"KENYON","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FIONA","family":"BROWNE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ROBERT J.","family":"D'AMATO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1006\/exer.1997.0292_RF1","unstructured":"Blascke, G. Kraft, H. P. Fickentscher, K. K\u00f6hler, F. 1979, Chromatographische racemattrennung von thalidomid und teratogene wirkung der enantiomere. Arzneim. Forsch\/Drug Res. 29, 1640, 2"},{"key":"10.1006\/exer.1997.0292_RF2","doi-asserted-by":"crossref","unstructured":"Cahen, R. 1964, Evaluation of the teratogenicity of drugs. Clin. Pharmacol. Ther. 5, 480, 514","DOI":"10.1002\/cpt196454480"},{"key":"10.1006\/exer.1997.0292_RF3","doi-asserted-by":"crossref","unstructured":"Carlesimo, M. Giustini, S. Rossi, A. Bonaccorsi, P. Calvieri, S. 1995, Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J. Am. Acad. Derm. 32, 866, 9","DOI":"10.1016\/0190-9622(95)91549-4"},{"key":"10.1006\/exer.1997.0292_RF4","doi-asserted-by":"crossref","unstructured":"D'Amato, R. J. Loughnan, M. S. Flynn, E. Folkman, J. 1994, Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 91, 4082, 5","DOI":"10.1073\/pnas.91.9.4082"},{"key":"10.1006\/exer.1997.0292_RF5","doi-asserted-by":"crossref","unstructured":"Fabro, S. Smith, R. L. Williams, R. T. 1967a, The fate of [14, Biochem. J. 1045, 565, 9","DOI":"10.1042\/bj1040565"},{"key":"10.1006\/exer.1997.0292_RF6","doi-asserted-by":"crossref","unstructured":"Fabro, S. Smith, R. Williams, R. 1967b, Toxicity and teratogenicity of optical isomers of thalidomide. Nature, 215, 296, 8","DOI":"10.1038\/215296a0"},{"key":"10.1006\/exer.1997.0292_RF7","doi-asserted-by":"crossref","unstructured":"Ferrar, N. Henzel, W. J. 1989, Pituitary follicular cells secrete a novel heparin binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 162, 851, 8","DOI":"10.1016\/0006-291X(89)92678-8"},{"key":"10.1006\/exer.1997.0292_RF8","doi-asserted-by":"crossref","unstructured":"Field, E. O. Gibbs, J. E. Tucker, D. L. Hellmann, K. 1966, Effect of thalidomide on graft-versus-host reaction. Nature, 211 (5055), 1308, 10","DOI":"10.1038\/2111308a0"},{"key":"10.1006\/exer.1997.0292_RF9","doi-asserted-by":"crossref","unstructured":"Friedlander, M. Brooks, P. C. Shaffer, R. W. Kincaid, C. M. Varner, J. A. Cheresh, D. A. 1995, Definition of two angiogenic pathways by distinct alpha integrins. Science, 70, 1500, 2","DOI":"10.1126\/science.270.5241.1500"},{"key":"10.1006\/exer.1997.0292_RF10","doi-asserted-by":"crossref","unstructured":"Gardner-Medwin, J. M. Smith, N. J. Powell, R. J. 1994, Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann. Rheumatol. Disease, 53 (12), 828, 32","DOI":"10.1136\/ard.53.12.828"},{"key":"10.1006\/exer.1997.0292_RF11","doi-asserted-by":"crossref","unstructured":"Gershbein, L. L. 1991, The thalidomide analog EM12, enhances 1,2-dimethyhydrazine induction of rat colon adenocarcinomas. Cancer Letter, 60, 129, 33","DOI":"10.1016\/0304-3835(91)90219-8"},{"key":"10.1006\/exer.1997.0292_RF12","doi-asserted-by":"crossref","unstructured":"Guex-Crosier, Y. Pittet, N. Herbort, C. P. 1995, The effect of Thalidomide and Supidimide on endotoxin-induced uveitis in rats. Graefe's Arch. Klin. Exp. Ophthalmol. 233 (2), 990, 3","DOI":"10.1007\/BF00241478"},{"key":"10.1006\/exer.1997.0292_RF13","doi-asserted-by":"crossref","unstructured":"Heger, W. Schmahl, H. Klug, S. Felies, A. Nau, H. Merker, H. Neubert, D. 1994, Embryotoxic effects of thalidomide derivates in the Non-human primate callithrix jacchus. 5. Teratogenicity of ug kg-1, Terato. Carcino. Mut. 14, 115, 22","DOI":"10.1002\/tcm.1770140303"},{"key":"10.1006\/exer.1997.0292_RF14","unstructured":"Jackson, A. Schumacher, H. J. 1980, Identification of urinary metabolites of EM12N, Can. J. Pharmacol. Sci. 15 (2), 21, 3"},{"key":"10.1006\/exer.1997.0292_RF15","doi-asserted-by":"crossref","unstructured":"Kean, W. F. Lock, C. Howard-Lock, H. E. 1991, Chirality in antirheumatic drugs. Lancet, 338, 1565, 8","DOI":"10.1016\/0140-6736(91)92382-C"},{"key":"10.1006\/exer.1997.0292_RF16","unstructured":"Kenyon, B. M. Voest, E. E. Chen, C. Flynn, E. Folkman, J. D'Amato, R. J. 1996, A model of angiogenesis in the mouse cornea. Invest. Ophthalmol. Vis. Sci. 37, 1625, 32"},{"key":"10.1006\/exer.1997.0292_RF17","doi-asserted-by":"crossref","unstructured":"Kocher-Becker, U. Kocher, W. 1982, Teratogenic activity of a hydrolytic thalidomide metabolite in mice. Naturwissenschaften, 69, 191, 2","DOI":"10.1007\/BF00364900"},{"key":"10.1006\/exer.1997.0292_RF19","doi-asserted-by":"crossref","unstructured":"Lenz, W. 1962, Thalidomide and congenital abnormalities. Lancet, 1, 45","DOI":"10.1016\/S0140-6736(62)92665-X"},{"key":"10.1006\/exer.1997.0292_RF20","doi-asserted-by":"crossref","unstructured":"McBride, W. G. 1961, Thalidomide and congenital abnormalities. Lancet, 2, 1358","DOI":"10.1016\/S0140-6736(61)90927-8"},{"key":"10.1006\/exer.1997.0292_RF21","doi-asserted-by":"crossref","unstructured":"Moreira, A. Sampaio, E. Zmuidzinas, A. Frindt, A. Smith, K. Kaplan, G. 1993, Thalidomide exerts its inhibitory action on tumor necrosis alpha (TNF-alpha) by enhancing mRNA degradation. J. Exp. Med. 177, 1675, 80","DOI":"10.1084\/jem.177.6.1675"},{"key":"10.1006\/exer.1997.0292_RF22","doi-asserted-by":"crossref","unstructured":"Neubert, R. Hinz, N. Thiel, R. Neubert, D. 1996, Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide. Life Sci. 58 (4), 295, 316","DOI":"10.1016\/0024-3205(95)02290-2"},{"key":"10.1006\/exer.1997.0292_RF23","doi-asserted-by":"crossref","unstructured":"Nishimura, K. Hashimoto, Y. Iwasaki, S. 1994, (S)-form of alpha-methyl-N, Chem. Pharmacol. Bull. 42 (5), 1157, 9","DOI":"10.1248\/cpb.42.1157"},{"key":"10.1006\/exer.1997.0292_RF25","doi-asserted-by":"crossref","unstructured":"Sampaio, E. Sarno, E. Galilly, V. Cohn, Z. A. Kaplan, G. 1991, Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 173, 699, 703","DOI":"10.1084\/jem.173.3.699"},{"key":"10.1006\/exer.1997.0292_RF26","unstructured":"Schandene, L. Vandenbussche, P. Crusiaux, A. Alegre, M. L. Abramowitcz, D. Dupont, E. Content, J. Goldman, M. 1992, Differential effects of pentoxifylline on the production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) by monocytes and T cells. Immunology, 76, 30, 4"},{"key":"10.1006\/exer.1997.0292_RF27","doi-asserted-by":"crossref","unstructured":"Schmahl, H. J. Nau, H. Neubert, D. 1988, The enantiomers of the teratogenic thalidomide analogue EM12: 1. Ciral inversion and plasma pharmacokinetics in the marmoset monkey. Arch. Toxicol. 62, 200, 4","DOI":"10.1007\/BF00570140"},{"key":"10.1006\/exer.1997.0292_RF28","doi-asserted-by":"crossref","unstructured":"Schmahl, H. Heger, W. Nau, H. 1989, The enantiomers of the teratogenic thalidomide analogue EM12: 2. Chemical stability, stereoselectivity of metabolism and renal excretion in the marmoset monkey. Toxicol. Lett. 45, 23, 33","DOI":"10.1016\/0378-4274(89)90155-0"},{"key":"10.1006\/exer.1997.0292_RF29","doi-asserted-by":"crossref","unstructured":"Schroder, M. Risau, W. Hallman, R. Gautschi, P. Bohlen, P. 1987, Tumor necrosis factor alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc. Nat. Acad. Sci. U.S.A. 84, 5277, 81","DOI":"10.1073\/pnas.84.15.5277"},{"key":"10.1006\/exer.1997.0292_RF30","doi-asserted-by":"crossref","unstructured":"Schumacher, H. Smith, R. I. Williams, R. T. 1965a, The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br. J. Pharmacol. Chemother. 25, 324, 37","DOI":"10.1111\/j.1476-5381.1965.tb02053.x"},{"key":"10.1006\/exer.1997.0292_RF31","doi-asserted-by":"crossref","unstructured":"Schumacher, H. Smith, R. Williams, R. T. 1965b, The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br. J. Pharmacol. 25, 338, 51","DOI":"10.1111\/j.1476-5381.1965.tb02054.x"},{"key":"10.1006\/exer.1997.0292_RF32","unstructured":"Schumacher, H. Blake, D. Gurian, J. Gillette, J. 1967, A comparison of the teratogenic activity of thalidomide in rabbits and rats. J. Pharmacol. Exp. Therap. 160 (1), 189, 200"},{"key":"10.1006\/exer.1997.0292_RF33","unstructured":"Schumacher, H. J. Blake, D. A. Gillette, J. R. 1968, Disposition of thalidomide in rabbits and rats. J. Pharmacol. Exp. Ther. 160 (1), 201, 11"},{"key":"10.1006\/exer.1997.0292_RF34","doi-asserted-by":"crossref","unstructured":"Schumacher, H. Terapane, J. Jordan, R. Wilson, J. G. 1972, The teratogenic activity of a thalidomide analog, EM 12, in rabbits, rats and monkeys. Teratology, 5, 233, 40","DOI":"10.1002\/tera.1420050213"},{"key":"10.1006\/exer.1997.0292_RF35","unstructured":"Scott, W. J. Fradkin, R. Wilson, J. G. 1970, Non-confirmation of thalidomide induced teratogenesis in rats and mice. Teratology, 5, 33, 6"},{"key":"10.1006\/exer.1997.0292_RF36","doi-asserted-by":"crossref","unstructured":"Sheskin, J. 1965, Further observations with thalidomide in lepra reactions. Leprosy Review, 36, 183, 7","DOI":"10.5935\/0305-7518.19650036"},{"key":"10.1006\/exer.1997.0292_RF37","doi-asserted-by":"crossref","unstructured":"Sheskin, J. 1980, The treatment of lepra reactions in lepromatous leprosy. Fifteen years' experience with thalidomide. Int. J. Derm. 19, 318, 22","DOI":"10.1111\/j.1365-4362.1980.tb00342.x"},{"key":"10.1006\/exer.1997.0292_RF38","doi-asserted-by":"crossref","unstructured":"Shing, Y. Folkman, J. Sullivan, R. Butterfield, C. Murray, J. Klagsbrun, M. 1984, Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science, 223, 1296, 9","DOI":"10.1126\/science.6199844"},{"key":"10.1006\/exer.1997.0292_RF39","unstructured":"Sunderkotter, C. Roth, J. Sorg, C. 1990, Immunohistochemical detection of bFGF and TNF-alpha in the course of inflammatory angiogenesis in the mouse cornea. Am. J. Pathol. 137, 511, 15"},{"key":"10.1006\/exer.1997.0292_RF40","unstructured":"Szabo, K. T. Steelman, R. L. 1967, Effects of maternal thalidomide treatment on pregnancy, fetal development, and mortality of the offspring in random-bred mice. Am. J. Vet. Res. 28 (127), 1823, 8"},{"key":"10.1006\/exer.1997.0292_RF41","doi-asserted-by":"crossref","unstructured":"Vogelsang, G. B. Farmer, E. R. Hess, A. D. Altamonte, V. Beschoner, W. E. Jabs, D. A. Corio, R. L. Levin, L. S. Wingard, J. R. Santos, G. W. 1992, Thalidomide for the treatment of chronic graft-versus-host disease. N. Engl. J. Med. 326, 1055, 8","DOI":"10.1056\/NEJM199204163261604"}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448359790292X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448359790292X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T21:03:33Z","timestamp":1576616613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001448359790292X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1997,6]]}},"alternative-id":["S001448359790292X"],"URL":"https:\/\/doi.org\/10.1006\/exer.1997.0292","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[1997,6]]}}}